Abstract 26P
Background
Subcutaneous (SC) trastuzumab offers a distinctive approach to treat HER2-positive breast cancer in contrast with conventional intravenous (IV) infusion. SC can be administered at day care unit, which is potentially a big step forward with a more efficient treatment mode compared to IV administration at inpatient wards. This study aimed to quantify the impact of treatment mode transition by measuring its benefits to hospitals as well as patients in China.
Methods
This time-motion study was conducted in Tianjin Medical University Cancer Institute & Hospital, where breast cancer treatment mode was shifted from IV administration at inpatient ward to SC administration at day care unit. The duration of each specific task conducted by HCPs and the time patient spent were recorded by observers. Costs, including HCP salaries, medical consumables, and other relevant items, were collected from public sources. The study outcomes included hospital capacity improvements, time savings for HCPs, and cost reductions for hospital. Meanwhile, patients' time savings and cost of lost labor were also measured.
Results
The treatment mode transition significantly improved the hospital operation efficiency. For 80 patients visited per day, IV administration required 80 inpatient beds, but SC administration in day care unit only occupied 6 injection chairs, equals to a freeing up of around 24,960 bed-days annually for a hospital. Considering this optimized and reallocated inpatient resources, estimated potential benefits were CNY 68,902 per day and CNY 21,497,490 per year. In addition, the adoption of SC administration reduced nursing working hour by 81%. For patients and caregivers, the treatment time per cycle was 91% less than IV administrations, leading to total savings of CNY 19,681 per patient in terms of direct cost and productivity cost over a full course of treatment.
Conclusions
Besides saving time for HCPs and patients, trastuzumab SC can help optimize treatment process, improve overall quality and efficiency of healthcare system & hospital management, aligned with China policies of high-quality hospital development.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Tianjin Medical University Cancer Institute & Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
540P - Phase III study of serplulimab plus chemotherapy as first-line therapy for advanced squamous non-small cell lung cancer: ASTRUM-004 Asian subgroup
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
541P - Integrated analysis of randomized controlled trials IMpower130 and IMpower132 for advanced non-squamous non-small cell lung cancer (NSCLC)
Presenter: Hibiki Udagawa
Session: Poster Display
Resources:
Abstract
542P - First-line HLX07 plus serplulimab with or without chemotherapy versus serplulimab plus chemotherapy in advanced/recurrent squamous non-small cell lung cancer: A phase II study
Presenter: Zhen Wang
Session: Poster Display
Resources:
Abstract
543P - A multicenter retrospective study to investigate risk factors for immune checkpoint inhibitor-induced pneumonitis in non-small cell lung cancer patients with comorbid interstitial pneumonia
Presenter: Yuriko Ishida
Session: Poster Display
Resources:
Abstract
544P - Single cell level investigation of blood cells representing immune checkpoint inhibitor response in lung adenocarcinoma patients
Presenter: Juyong Seong
Session: Poster Display
Resources:
Abstract
545P - Completion of pembrolizumab in advanced non-small cell lung cancer: Real-world outcomes after two years of therapy (COPILOT)
Presenter: Andrew Fantoni
Session: Poster Display
Resources:
Abstract
546P - Combination therapy with anti-PD-1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation
Presenter: Akio Tada
Session: Poster Display
Resources:
Abstract
547P - Immunotherapy outcome in advanced/metastatic lung cancer patients in real-world experience: Indian data
Presenter: Naveen K
Session: Poster Display
Resources:
Abstract
548P - B-Myb acts as a mentor instant promoter in non-small cell lung cancer by modifying the PD-1/PD-L1 axis
Presenter: Pan Xu
Session: Poster Display
Resources:
Abstract
549P - Drug-induced interstitial lung disease in patients with non-small cell lung cancer treated with immunotherapy for postoperative recurrence: Evaluation of CT findings and histopathological findings of the background lung
Presenter: shodai fujimoto
Session: Poster Display
Resources:
Abstract